Company Overview and News

Hewlett Packard Enterprise: Cheap Enough To Buy

2018-05-23 seekingalpha
HP Enterprise reported a beat to Q2 earnings, the second consecutive beat since Antonio Neri took the reins from Meg Whitman.

Pure Storage (PSTG) Posts Narrower-Than-Expected Loss in Q1

2018-05-22 zacks
Pure Storage Inc. (PSTG - Free Report) reported non-GAAP loss of 7 cents per share in the first quarter of fiscal 2019, which was narrower than the Zacks Consensus Estimate by 5 cents. The figure was also below the year-ago loss of 12 cents per share.

Pure Storage: We've Been Here Before

2018-05-22 seekingalpha
It's the same old story with Pure Storage (PSTG): earnings beat, lackluster guidance, huge post-earnings drop. You'd think that investors would have gotten used to the pattern by now - fortunately for opportunists who can see longer term, recent history tells us that Pure Storage is almost always a strong buy on earnings dips. Last quarter, Pure Storage's Q4 earnings beat and in-line Q1 guidance caused the stock to tank by almost exactly the same amount - yet the company quickly recovered to flat and over the course of the quarter, shares appreciated by more than 20%.

Pure Storage's (PSTG) CEO Charlie Giancarlo on Q1 2019 Results - Earnings Call Transcript

2018-05-22 seekingalpha
Good afternoon. My name is Chris and I will be your conference operator today. At this time, I would like to welcome everyone to the Pure Storage Q1 Fiscal 2019 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]

After-hours buzz: ADBE, SHOP & more

2018-05-21 cnbc
Shares of Adobe jumped close to 2.5 percent after the bell, before paring gains slightly and settling up nearly 1 percent. The software company on Monday announced an $8 billion stock repurchase program, which extends a previous $2.5 billion program through 2021. Adobe CFO John Murphy said the program "is reflective of our strong cash flow expectations and balance sheet, and reinforces our commitment to returning value and excess cash to our stockholders.

Pure Storage 2019 Q1 - Results - Earnings Call Slides

2018-05-21 seekingalpha
The following slide deck was published by Pure Storage in conjunction with their 2019 Q1 earnings call.

PSTG / Pure Storage, Inc. 8-K (Current Report)


Spotlight On Gambling Reset And Banking Bill

2018-05-19 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.

What Does NetApp Expect in Fiscals 2018 and 2019?

2018-05-18 marketrealist
NetApp (NTAP) expects low-single-digit revenue growth in fiscal 2018 driven by product revenue growth. Analysts expect NetApp’s revenue to rise 6.4% YoY (year-over-year) to $5.9 billion in fiscal 2018. Its gross margin is expected to be 63%, and its operating margin is expected to expand 2% YoY to 19% in fiscal 2018.

Cramer's lightning round: Don't buy Apple suppliers right now

2018-05-16 cnbc
Cirrus Logic: "We're not really recommending the components players that go into Apple right now. It's just too hard."

Arista: Is It A Rising Or Setting Sun?

2018-05-14 seekingalpha
The shares have become somewhat controversial over time, with 15 buy recommendations compared to nine hold recommendations, reported on First Call.

Pure Storage Hits 52-Week High: What's Behind the Rally?

2018-05-10 zacks
Shares of Pure Storage, Inc (PSTG - Free Report) rallied to a new 52-week high of $23.19 on May 10, closing marginally lower at $23.13. The company has a market capital of $4.84 billion.

PSTG / Pure Storage, Inc. DEF 14A


PSTG / Pure Storage, Inc. DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Secu

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 74624M102